Mostra i principali dati dell'item
Anti-a actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1
dc.creator | Zachou, K. | en |
dc.creator | Oikonomou, K. | en |
dc.creator | Renaudineau, Y. | en |
dc.creator | Chauveau, A. | en |
dc.creator | Gatselis, N. | en |
dc.creator | Youinou, P. | en |
dc.creator | Dalekos, G. N. | en |
dc.date.accessioned | 2015-11-23T10:54:37Z | |
dc.date.available | 2015-11-23T10:54:37Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.1111/j.1365-2036.2011.04908.x | |
dc.identifier.issn | 0269-2813 | |
dc.identifier.uri | http://hdl.handle.net/11615/34785 | |
dc.description.abstract | Background We reported that combined presence of autoantibodies (Abs) against filamentous-actin (AFA) and a-actinin are specific for autoimmune hepatitis type 1 (AIH-1) diagnosis. Aim To explore our data and assess whether anti-a-actinin and AFA Abs could be used as indicators of response to treatment and predictors of AIH-1 flares in a large cohort of AIH-1 patients. Methods Seven hundred and sixty-four serial serum samples of 86 consecutive AIH-1 patients, 509 pathological and 110 normal controls were tested for the presence of anti-a-actinin and AFA Abs by an in-house IgG-specific ELISA and a standardised commercially available ELISA respectively. Patients sera were divided into baseline group (active disease before treatment initiation, n = 86) and then according to treatment response into group A-responders (n = 40 patients), group B-relapsers/incomplete responders (n = 37 patients) and group C-not-treated (n = 9 patients). Results Anti-a-actinin and AFA levels were significantly higher at baseline. Double reactivity against a-actinin and AFA was associated with disease activity (OR 4.9; 95% CI: 2.79). Anti-a-actinin optical densities (ODs) before treatment decreased significantly at first remission (P < 0.05). Treatment response was associated with anti-a-actinin Abs negativity before treatment (OR 3.4; 95% CI: 1.38.9) and absence of double positivity for anti-a-actinin and AFA Abs before treatment (OR 3.8; 95% CI: 1.410.4). Responders had lower baseline levels of anti-a-actinin than relapsers and/or incomplete responders (P = 0.002). Binary logistic regression revealed lower levels of anti-a-actinin as the only independent predictors of response (P = 0.05). Conclusions Anti-a-actinin Abs at baseline appear to predict treatment response and therefore they might be used for monitoring treatment outcome in AIH-1. | en |
dc.source | Alimentary Pharmacology & Therapeutics | en |
dc.source.uri | <Go to ISI>://WOS:000297922600012 | |
dc.subject | SOLUBLE LIVER ANTIGEN | en |
dc.subject | B-VIRUS INFECTION | en |
dc.subject | ALPHA-ACTININ | en |
dc.subject | DNA ANTIBODIES | en |
dc.subject | LUPUS NEPHRITIS | en |
dc.subject | ANTIACTIN ANTIBODIES | en |
dc.subject | SEVERE FORM | en |
dc.subject | AUTOANTIBODIES | en |
dc.subject | DISEASES | en |
dc.subject | SPECIFICITY | en |
dc.subject | Gastroenterology & Hepatology | en |
dc.subject | Pharmacology & Pharmacy | en |
dc.title | Anti-a actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1 | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |